Skip to main content

Arbitration Panel Rules Operon Must Pay Qiagen $2.1M

NEW YORK (GenomeWeb News) – Operon Biotechnologies must pay Qiagen $2.1 million as a result of an arbitration panel ruling, Qiagen disclosed in a regulatory filing.

In its quarterly earning document filed with the US Securities and Exchange Commission earlier this month, Qiagen said that the arbitration panel ruled in its favor in a supply agreement dispute between the two companies.

In 2009, Operon began arbitration proceedings against Qiagen, claiming Qiagen failed to comply with the preferred supplier provisions of their agreement, resulting in lost profits and other damages. Qiagen disputed the allegations and asserted counterclaims, and in June the arbitration panel ruled in favor of Qiagen on all claims, Qiagen said.

Operon is now Eurofins MWG Operon, based in Ebersberg, Germany, and offers custom oligos, and oligos and sequencing services.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.